uniQure N.V. Share Price & Technical Analysis
QURE · $24.19 (-2.30%)
Healthcare / Biotechnology
$24.19
-2.30%
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
22% return in May, 3% avg return in past 3 year May month.
86% return in 2026, 124% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | -31% | 78% | 23% | 22% | – | – | – | – | – | – | – | 86% |
| 25 | -12% | -13% | -19% | 37% | -3% | -5% | -1% | 17% | 258% | 17% | 20% | -10% | 286% |
| 24 | -16% | 4% | -10% | -15% | 11% | -13% | 75% | -26% | -16% | 16% | 3% | 172% | 185% |
| 23 | -7% | -1% | -4% | -3% | -1% | -40% | -9% | -16% | -24% | -15% | 21% | 0% | -100% |
| 22 | -14% | -6% | 9% | -18% | -4% | 29% | 37% | -22% | -3% | -4% | 39% | -14% | 30% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Strong
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.83B
P/E ratio
—
52W high
$71.50
52W low
$8.73
Volume
6,80,412
Beta
0.87
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is uniQure N.V. share price today?
- uniQure N.V. (QURE) last traded around $24.19 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does QURE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for QURE. Download the app for real-time alerts.
- How can I analyze uniQure N.V. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.